SGLT2 inhibitors (SGLT2i) are a class of antihyperglycemic drugs which have demonstrated significant extra-glycemic benefits, particularly in terms of cardiovascular and renal protection [3] in type 2 diabetes. Here, SLC5A2 is linked to type 2 diabetes mellitus.